<?xml version="1.0" encoding="UTF-8"?>
<jcr:root xmlns:jcr="http://www.jcp.org/jcr/1.0" xmlns:nt="http://www.jcp.org/jcr/nt/1.0" xmlns:mix="http://www.jcp.org/jcr/mix/1.0" xmlns:cq="http://www.day.com/jcr/cq/1.0" xmlns:sling="http://sling.apache.org/jcr/sling/1.0"
    jcr:primaryType="cq:Page">
    <jcr:content
        cq:lastModified="{Date}2024-02-08T16:27:46.072Z"
        cq:lastModifiedBy="reference-adjustment-service"
        cq:template="/conf/menarini-berlinchemie/settings/wcm/templates/menarini---details-news"
        jcr:isCheckedOut="{Boolean}true"
        jcr:mixinTypes="[mix:versionable]"
        jcr:primaryType="cq:PageContent"
        jcr:title="Helsinn Grants Exclusive Licensing Rights to Berlin-Chemie Menarini, for ONICIT&lt;sup>®&lt;/sup>/ALOXI&lt;sup>®&lt;/sup> and AKYNZEO&lt;sup>®&lt;/sup> in Russia and CIS region"
        jcr:uuid="e75a6a93-f983-4b11-a770-dee7082c3cb2"
        sling:resourceType="menarinimaster/components/page"
        dnnNewsIdentifier="8a1c191b-1720-40aa-88de-c68d8076ed34-908">
        <root
            jcr:primaryType="nt:unstructured"
            sling:resourceType="menarinimaster/components/container"
            layout="responsiveGrid">
            <container
                jcr:primaryType="nt:unstructured"
                sling:resourceType="menarinimaster/components/container"
                layout="responsiveGrid">
                <internalheader
                    jcr:primaryType="nt:unstructured"
                    jcr:title="News &amp; Medien"
                    sling:resourceType="menarinimaster/components/internalheader"
                    altValueFromDAM="{Boolean}false"
                    imageFromPageImage="{Boolean}false"
                    titleFromPage="{Boolean}false"/>
                <section
                    jcr:lastModified="{Date}2023-05-23T15:09:53.441Z"
                    jcr:lastModifiedBy="a.messori@adiacent.com"
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/section">
                    <wrapper
                        jcr:lastModified="{Date}2023-05-23T15:11:01.995Z"
                        jcr:lastModifiedBy="a.messori@adiacent.com"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/wrapper">
                        <breadcrumb
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/breadcrumb"/>
                    </wrapper>
                </section>
                <container
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/container"
                    layout="responsiveGrid">
                    <internalmenu
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/internalmenu"
                        navigationRoot="/content/menarini-berlinchemie/de/menarini-group-news"
                        structureStart="{Long}0">
                        <cq:responsive jcr:primaryType="nt:unstructured">
                            <default
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="3"/>
                            <tablet
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="4"/>
                            <phone
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </internalmenu>
                    <container
                        cq:styleIds="[1684742346871]"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/container"
                        layout="responsiveGrid">
                        <news_data
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/news_data"
                            newsDate="{Date}2020-01-27T04:39:00.000Z">
                            <cq:responsive jcr:primaryType="nt:unstructured">
                                <default
                                    jcr:primaryType="nt:unstructured"
                                    offset="0"
                                    width="9"/>
                            </cq:responsive>
                        </news_data>
                        <title
                            cq:styleIds="[1653552493699]"
                            jcr:lastModified="{Date}2023-06-07T15:16:13.835Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/title"
                            linkTarget="_self"
                            type="h2"/>
                        <image
                            jcr:lastModified="{Long}1707398376567"
                            jcr:lastModifiedBy="Importer"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/image"
                            displayPopupTitle="true"
                            fileReference="/content/dam/menarini-berlinchemie/assets/news/img-Senza-titolo-21.jpg"
                            imageFromPageImage="{Boolean}false"
                            isDecorative="true"
                            linkTarget="_self"
                            titleValueFromDAM="false">
                            <cq:responsive jcr:primaryType="nt:unstructured">
                                <default
                                    jcr:primaryType="nt:unstructured"
                                    offset="2"
                                    width="4"/>
                                <phone
                                    jcr:primaryType="nt:unstructured"
                                    offset="1"
                                    width="10"/>
                            </cq:responsive>
                        </image>
                        <spacer
                            jcr:lastModified="{Date}2023-06-07T15:17:27.212Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/spacer"
                            spacer="40"/>
                        <text
                            jcr:lastModified="{Long}1707398376577"
                            jcr:lastModifiedBy="Importer"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/text"
                            text="&lt;p>&lt;img align=&quot;left&quot; alt=&quot;&quot; src=&quot;/Portals/31/Images/notizie/logo_Helsinn.jpg&quot; style=&quot;max-width: 250px;&quot; /> &lt;img align=&quot;right&quot; alt=&quot;&quot; src=&quot;/Portals/31/Images/notizie/logo_berlin-chemie.jpg&quot; style=&quot;max-width: 250px;&quot; />&lt;/p>&#xa;&#xa;&lt;p>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;ul>&#xa; &lt;li>Berlin-Chemie AG has been granted exclusive rights to import, distribute, promote, market and sell AKYNZEO&amp;reg; and ONICIT&amp;reg; (ALOXI&amp;reg;) in Russia and CIS region from January 2020&lt;/li>&#xa; &lt;li>The two products will provide clinicians and patients with a comprehensive offering to manage chemotherapy-induced nausea and vomiting&lt;/li>&#xa;&lt;/ul>&#xa;&#xa;&lt;p>&lt;strong>Lugano, Switzerland and Berlin, Germany, January 27, 2020&lt;/strong>: Helsinn Group (&amp;ldquo;Helsinn&amp;rdquo;), a Swiss pharmaceutical group focused on building quality cancer care products, has granted exclusive licensing rights to commercialize AKYNZEO&lt;sup>&amp;reg;&lt;/sup> and ONICIT&lt;sup>&amp;reg;&lt;/sup> (ALOXI&lt;sup>&amp;reg;&lt;/sup>) in Russia and the CIS region for the prevention of chemotherapy-induced nausea and vomiting (CINV) to Berlin-Chemie AG (&amp;ldquo;Berlin-Chemie&amp;rdquo;), the German-based affiliate of the Menarini Group.&lt;/p>&#xa;&#xa;&lt;p>AKYNZEO&lt;sup>&amp;reg;&lt;/sup>, a fixed dose combination anti-emetic therapy targeting both critical pathways of acute and delayed CINV, was granted registration in Russia in October 2019 and the product will be launched in the country in 2020.&lt;/p>&#xa;&#xa;&lt;p>ONICIT&lt;sup>&amp;reg;&lt;/sup>, an anti-emetic for the prevention of CINV, was registered in Russia in 2011 and will be relaunched with AKYNZEO&lt;sup>&amp;reg;&lt;/sup>.&lt;/p>&#xa;&#xa;&lt;p>Besides Russia, the licensing agreements with Berlin-Chemie cover the following territories: Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine and Uzbekistan. AKYNZEO&lt;sup>&amp;reg; &lt;/sup>has obtained a registration in Ukraine and Kazakhstan while ALOXI&lt;sup>&amp;reg;&lt;/sup> holds a registration in Ukraine.&lt;/p>&#xa;&#xa;&lt;p>Under the terms of the agreements, Helsinn will retain all international development rights, including clinical development activities, and the supply of AKYNZEO&lt;sup>&amp;reg;&lt;/sup> and ONICIT/&lt;sup>&amp;reg;&lt;/sup>ALOXI&lt;sup>&amp;reg;&lt;/sup>. Berlin-Chemie will have the exclusive rights to promote, distribute and commercialize AKYNZEO&lt;sup>&amp;reg;&lt;/sup> and ONICIT&lt;sup>&amp;reg;&lt;/sup>/ALOXI&lt;sup>&amp;reg; &lt;/sup>in all countries of the assigned territories.&lt;/p>&#xa;&#xa;&lt;p>Riccardo Braglia, Helsinn Group Vice Chairman and CEO commented: &amp;ldquo;We&amp;rsquo;re delighted to have signed these agreements with Berlin-Chemie, which has established a strong presence and recognition in Russia and the CIS region. We look forward to being able to offer cancer patients greater choice for treating CINV, which remains a major issue during chemotherapy.&amp;rdquo;&lt;/p>&#xa;&#xa;&lt;p>&amp;ldquo;This is an important step for cancer patients across Russia and the CIS region. We look forward to working closely with Helsinn as we seek to launch AKYNZEO&lt;sup>&amp;reg;&lt;/sup> and re-launch ONICIT&lt;sup>&amp;reg; &lt;/sup>in the year ahead. We have been impressed by Helsinn&amp;rsquo;s commitment to the highest quality cancer care products and are pleased to extend our partnership with them.&amp;rdquo; said Michael Sirotovitch, COO of Berlin-Chemie AG.&lt;/p>"
                            textIsRich="true"/>
                        <cq:responsive jcr:primaryType="nt:unstructured">
                            <default
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <tablet
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <phone
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </container>
                </container>
            </container>
        </root>
        <cq:featuredimage
            jcr:primaryType="nt:unstructured"
            sling:resourceType="core/wcm/components/image/v3/image"
            altValueFromDAM="{Boolean}false"
            fileReference="/content/dam/menarini-berlinchemie/assets/news/img-Senza-titolo-21.jpg"/>
    </jcr:content>
</jcr:root>
